治療用血漿交換の世界市場規模：適応疾患別、エンドユーザー別、地域範囲別および予測

治療用血漿交換の市場規模と予測

治療用血漿交換市場規模は、2024年に11億5,000万米ドルと評価され、2026～2032年にかけてCAGR 7.5%で成長し、2032年には21億9,000万米ドルに達すると予測されます。

治療的血漿交換（TPE）は、患者の血液から血漿を除去し、生理食塩水やドナー血漿などの代替液と交換する医療処置です。

治療的血漿交換の主要目的は、様々な疾患や症状の原因となる抗体、毒素、異常タンパク質など、血漿中に含まれる有害物質を除去することです。

治療的血漿交換は、自己免疫疾患（例：ギラン・バレー症候群、重症筋無力症）、血液疾患（例：血栓性血小板減少性紫斑病）、特定の腎臓病など、さまざまな症状の治療に一般的に利用されています。

このプロセスには通常、血液を成分に分離するアフェレーシス装置が使用されます。血漿は除去され、残りの血球は患者に戻される前に交換液と混合されます。

世界の治療用血漿交換市場力学

世界の治療用血漿交換市場を形成している主要市場力学は以下の通りです。

主要促進要因

自己免疫疾患の有病率の上昇：重症筋無力症やギラン・バレー症候群などの自己免疫疾患の罹患率の増加が、治療用血漿交換の需要を大きく牽引しています。例えば、米国国立衛生ラボ（National Institutes of Health）は、重症筋無力症の有病率は毎年全世界で10万人あたり約20人が罹患していると報告しており、効果的な治療オプションの必要性を強調しています。

高齢者の増加：高齢化社会は、治療用血漿交換を必要とする慢性疾患に罹患しやすくなります。 2050年までに、欧州の一部の国では人口の30％以上が65歳以上になると予測されており、加齢に関連した健康問題に対処する治療用血漿交換のような治療法の需要が高まっています。

技術の進歩：治療的血漿交換技術の絶え間ない進歩は、その有効性と安全性を高め、好ましい治療選択肢となっています。より効率的なアフェレシス装置の開発とプロトコルの改善が市場成長を促進すると予想されます。

ヘルスケア支出の増加：特に北米におけるヘルスケア支出の増加は、治療的血漿交換のような先進治療へのアクセスを容易にしています。米国では、2021年のヘルスケア支出は約4兆3,000億米ドルであり、革新的な治療法の利用を支えています。

主要課題

機器と消耗品の高コスト：血漿交換療法には、アフェレシス装置などの特殊な機器や、チューブやフィルターなどの使い捨て部品が必要なため、多額の費用がかかります。この高コストが、特に開発途上地域のヘルスケアプロバイダや患者のアクセスを制限する可能性があります。

限られた市場需要：治療用血漿交換製品は、より広く使用されている医療用製品と比較して、市場需要が比較的限られている場合があります。このように生産規模が限られているため、単位あたりのコストが高くなり、メーカーが規模の経済を達成することが困難になる可能性があります。

規制上の課題：安全性と有効性に関する厳格な規制基準への準拠は、治療用血漿交換デバイスや消耗品の承認プロセスを複雑にする可能性があります。このため、新製品の市場参入が遅れ、開発コストが増加する可能性がある2。

副作用の可能性：治療的血漿交換を受ける患者は、アレルギー反応、低血圧、電解質不均衡などの副作用を経験する可能性があります。このような合併症は、一部のヘルスケアプロバイダが治療選択肢として治療的血漿交換を採用することを躊躇させ、市場成長の可能性を制限する可能性があります。

主要動向

適応の拡大：治療的血漿交換の適応症は大幅に拡大し、現在では従来型用途を超えた幅広い疾患を包含しています。これには自己免疫疾患、神経疾患、腎疾患などが含まれます。例えば、ある調査によると、治療的血漿交換手技の36.8%を腎疾患が占めており、これはさまざまな医療状況における治療的血漿交換の有効性が認識されつつあることを反映しています。

処置量の増加：治療的血漿交換の年間実施件数は顕著に増加しています。韓国のデータによると、2008～2017年にかけてTPEの実施件数は約3.7倍に増加しており、この治療法が臨床現場で受け入れられ、利用されつつあることを示しています。

技術の進歩：アフェレシス技術の革新は、治療的血漿交換手技の効率性と安全性を高めています。先進的なアフェレシス装置の導入は、患者の予後を改善し、プロセスを合理化し、市場の成長に寄与すると期待されています。

認識と受容の高まり：複雑な病態を管理するためのTPEの利点に関するヘルスケア提供者の意識の高まりが、TPEの採用を後押ししています。例えば、CDCは米国で年間2万～4万件のギラン・バレー症候群の症例を報告しており、TPEのような効果的な治療オプションの必要性を強調しています。

目次

第1章 世界の治療用血漿交換市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の治療用血漿交換市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 治療用血漿交換の世界市場：適応疾患別

• 概要
• 神経疾患
• 腎臓疾患
• 血液疾患
• 代謝疾患
• その他

第6章 治療用血漿交換の世界市場：エンドユーザー別

• 概要
• 病院
• 専門クリニック
• 外来手術センター

第7章 治療用血漿交換の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界の治療用血漿交換市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第9章 企業プロファイル

• Asahi Kasei Corporation
• Baxter International, Inc.
• Terumo Corporation
• B. Braun Melsungen AG
• Fresenius Kabi AG
• Kawasumi Laboratories, Inc.
• Haemonetics Corporation
• Cerus Corporation
• Hemacare Corporation
• Medica S.p.A

第10章 主要開発

• 製品上市/開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Therapeutic Plasma Exchange Market Size And Forecast

Therapeutic Plasma Exchange Market size was valued at USD 1.15 Billion in 2024 and is projected to reach USD 2.19 Billion by 2032, growing at a CAGR of 7.5% from 2026 to 2032.

Therapeutic plasma exchange (TPE) is a medical procedure that involves the removal of plasma from a patient's blood and its replacement with a substitute fluid, such as saline or donor plasma.

The primary goal of therapeutic plasma exchange is to eliminate harmful substances found in the plasma, such as antibodies, toxins, or abnormal proteins, which may be responsible for various diseases and symptoms.

therapeutic plasma exchange is commonly utilized to treat a range of conditions, including autoimmune diseases (e.g., Guillain-Barre syndrome, myasthenia gravis), blood disorders (e.g., thrombotic thrombocytopenic purpura), and certain kidney diseases.

The process typically involves using an apheresis machine that separates blood into its components. Plasma is removed, and the remaining blood cells are mixed with a replacement fluid before being returned to the patient.

Global Therapeutic Plasma Exchange Market Dynamics

The key market dynamics that are shaping the global therapeutic plasma exchange market include:

Key Drivers:

Rising Prevalence of Autoimmune Diseases: The increasing incidence of autoimmune disorders, such as myasthenia gravis and Guillain-Barre syndrome, is significantly driving the demand for therapeutic plasma exchange . For instance, the National Institutes of Health reported that the prevalence of myasthenia gravis affects about 20 per 100,000 people globally each year, highlighting the need for effective treatment options.

Growing Geriatric Population: The aging population is more susceptible to chronic diseases that require therapeutic plasma exch By 2050, it is projected that over 30% of the population in some European countries will be over 65 years old, increasing the demand for therapies like therapeutic plasma exchange that address age-related health issues.

Technological Advancements: Continuous advancements in therapeutic plasma exchange technology enhance its effectiveness and safety, making it a preferred treatment option. The development of more efficient apheresis machines and improved protocols are expected to drive market growth.

Increased Healthcare Spending: Rising healthcare expenditures, particularly in North America, are facilitating access to advanced treatments like therapeutic plasma exchange. In the U.S., healthcare spending was approximately $4.3 trillion in 2021, supporting the availability of innovative therapies.

Key Challenges:

High Cost of Equipment and Consumables: The cost associated with therapeutic plasma exchange procedures is significant due to the need for specialized equipment, such as apheresis machines, and single-use disposable components like tubing and filters. This high cost can limit accessibility for healthcare providers and patients, particularly in developing regions.

Limited Market Demand: Therapeutic plasma exchange products may have relatively limited market demand compared to more widely used medical products. This limited scale of production can lead to higher per-unit costs, making it challenging for manufacturers to achieve economies of scale.

Regulatory Challenges: Compliance with stringent regulatory standards for safety and efficacy can complicate the approval process for therapeutic plasma exchange devices and consumables. This can delay market entry for new products and increase development costs2.

Potential Side Effects: Patients undergoing therapeutic plasma exchange may experience side effects such as allergic reactions, hypotension, or electrolyte imbalances. These complications can deter some healthcare providers from adopting therapeutic plasma exchange as a treatment option, limiting its market growth potential.

Key Trends:

Expansion of Indications: The indications for therapeutic plasma exchange have broadened significantly, now encompassing a wide range of conditions beyond traditional uses. This includes autoimmune diseases, neurological disorders, and renal diseases. For instance, a study indicated that renal diseases accounted for 36.8% of therapeutic plasma exchange procedures, reflecting a growing recognition of therapeutic plasma exchange's effectiveness in various medical contexts.

Increased Procedure Volume: There has been a notable increase in the number of therapeutic plasma exchange procedures performed annually. Data from South Korea showed that the number of TPE procedures increased approximately 3.7 times from 2008 to 2017, indicating a rising acceptance and utilization of this therapy in clinical practice.

Technological Advancements: Innovations in apheresis technology are enhancing the efficiency and safety of therapeutic plasma exchange procedures. The introduction of advanced apheresis machines is expected to improve patient outcomes and streamline the process, contributing to market growth.

Growing Awareness and Acceptance: Increased awareness among healthcare providers regarding the benefits of TPE for managing complex conditions is driving its adoption. For example, the CDC reported between 20,000 to 40,000 cases of Guillain-Barre syndrome annually in the U.S., highlighting the need for effective treatment options like TPE.

Global Therapeutic Plasma Exchange Market Regional Analysis

Here is a more detailed regional analysis of the global therapeutic plasma exchange market:

North America:

The North American therapeutic plasma exchange market is projected to reach approximately USD 280 Million by 2027, growing at a CAGR of 6.2% from 2022 to 2027, reflecting robust market potential.

The region has a high prevalence of autoimmune diseases, with the National Institutes of Health reporting that conditions like myasthenia gravis affect approximately 20 per 100,000 people annually, driving demand for TPE treatments.

According to the American Heart Association, nearly 92.1 million individuals in the U.S. suffered from cardiovascular diseases in 2018, which increases the need for therapeutic plasma exchange interventions.

North America benefits from an advanced healthcare infrastructure that supports the widespread adoption of TPE procedures, ensuring patient access to effective treatments.

Europe:

The European market is projected to grow significantly, with estimates indicating it will reach approximately USD 19 Billion by 2032, reflecting a CAGR of 7.5% from 2026 to 2032. This growth is driven by increasing prevalence of neurological, renal, and hematological disorders.

Many European countries have established healthcare systems that ensure broad access to medical treatments, including therapeutic plasma exchange. This accessibility enhances patient care and treatment outcomes.

The presence of numerous biotech companies and research institutions in Europe supports innovation and development in therapeutic plasma exchange technologies, contributing to the market's expansion.

The aging population in Europe is increasing the demand for chronic disease management solutions, with projections indicating that by 2030, nearly 20% of the European population will be over 65 years old, further driving the need for therapies like therapeutic plasma exchange.

Global Therapeutic Plasma Exchange Market: Segmentation Analysis

The Global Therapeutic Plasma Exchange Market is segmented on the basis of Disease Indications, End-User and Geography.

Therapeutic Plasma Exchange Market, By Disease Indications

• Neurological Disorders
• Renal Disorders
• Hematology Disorders
• Metabolic Disorders
• Others

Based on Disease Indications, the Global Therapeutic Plasma Exchange is divided into Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders, and Others. The neurological disorder segment is expected to capture the largest market share due to the high incidence of these diseases, especially in the aging population. Reports indicate that neurological conditions account for a substantial portion of TPE applications.

Therapeutic Plasma Exchange Market, By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

Based on End-User, the Global Therapeutic Plasma Exchange is divided into Hospitals, Specialty Clinics, and Ambulatory Surgical Centers. Hospitals account for a significant share of the therapeutic plasma exchange market due to their ability to accommodate patients requiring extended care and monitoring during TPE procedures.

Therapeutic Plasma Exchange Market, By Geography

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America

Based on Geography, the Therapeutic Plasma Exchange Market is classified into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. The North American therapeutic plasma exchange market is projected to reach approximately USD 280 Million by 2027, growing at a CAGR of 6.2% from 2022 to 2027, reflecting robust market potential.

Key Players

The "Global Therapeutic Plasma Exchange Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun Melsungen AG, Fresenius Kabi AG, Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Hemacare Corporation, Medica S.p.A., and others.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Therapeutic Plasma Exchange Market Recent Developments
• In June 2023, Terumo Blood and Cell Technologies launched the Rika Plasma Donation System in the United States. This system is designed to enhance the efficiency and safety of plasma collection, addressing the growing demand for treatments using plasma fractionation products.
• In September 2023, Fresenius Kabi AG launched an updated version of its apheresis systems, featuring improved automation and user-friendly interfaces to streamline the therapeutic plasma exchange process in clinical settings.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET, BY DISEASE INDICATION

• 5.1 Overview
• 5.2 Neurological Disorders
• 5.3 Renal Disorders
• 5.4 Hematology Disorders
• 5.5 Metabolic Disorders
• 5.6 Others

6 GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Specialty Clinics
• 6.4 Ambulatory Surgical Centers

7 GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Asahi Kasei Corporation
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Baxter International, Inc.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Terumo Corporation
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 B. Braun Melsungen AG
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Fresenius Kabi AG
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Kawasumi Laboratories, Inc.
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Haemonetics Corporation
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Cerus Corporation
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Hemacare Corporation
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Medica S.p.A
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research